Paper37573408
FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations.
Pawlikowska P and 7 others. Oncogene, 2023. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations. Papers, record 37573408. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37573408
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia | Major topic |
| Fanconi Anemia Complementation Group A Protein | Major topic |
| Animals | |
| Mice | |
| Heterozygote | |
| Mutation | |
| Oncogenes |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 2 | 32025018 | The repertoire of mutational signatures in human cancer. | Nature | 2020 | https://conductscience.org/library/papers/32025018 | PubMed |
| 3 | 33194896 | DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. | Front Pediatr | 2020 | https://conductscience.org/library/papers/33194896 | PubMed |
| 4 | 29617664 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. | Cell Rep | 2018 | https://conductscience.org/library/papers/29617664 | PubMed |
| 5 | 25999502 | Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. | Science | 2015 | https://conductscience.org/library/papers/25999502 | PubMed |
| 6 | 25426837 | Age-related clonal hematopoiesis associated with adverse outcomes. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25426837 | PubMed |
| 7 | 12130514 | Heterozygous PU.1 mutations are associated with acute myeloid leukemia. | Blood | 2002 | https://conductscience.org/library/papers/12130514 | PubMed |
| 8 | 15146183 | Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. | Nat Genet | 2004 | https://conductscience.org/library/papers/15146183 | PubMed |
| 9 | 2827041 | Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. | Nature | 1988 | https://conductscience.org/library/papers/2827041 | PubMed |
| 10 | 31018969 | A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31018969 | PubMed |
| 11 | 28671687 | Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. | Nat Genet | 2017 | https://conductscience.org/library/papers/28671687 | PubMed |
| 12 | 26343801 | Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. | Nat Med | 2015 | https://conductscience.org/library/papers/26343801 | PubMed |
| 13 | 34938963 | KDM4B promotes acute myeloid leukemia associated with AML1-ETO by regulating chromatin accessibility. | FASEB Bioadv | 2021 | https://conductscience.org/library/papers/34938963 | PubMed |
| 14 | 8628313 | Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. | Mol Cell Biol | 1996 | https://conductscience.org/library/papers/8628313 | PubMed |
| 15 | 16338660 | Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. | Cancer Cell | 2005 | https://conductscience.org/library/papers/16338660 | PubMed |
| 16 | 32350520 | Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. | Blood | 2020 | https://conductscience.org/library/papers/32350520 | PubMed |
| 17 | 33512458 | Modeling and targeting of erythroleukemia by hematopoietic genome editing. | Blood | 2021 | https://conductscience.org/library/papers/33512458 | PubMed |
| 18 | 27094386 | Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway. | Cell Mol Life Sci | 2016 | https://conductscience.org/library/papers/27094386 | PubMed |
| 19 | 32466131 | The FANC/BRCA Pathway Releases Replication Blockades by Eliminating DNA Interstrand Cross-Links. | Genes (Basel) | 2020 | https://conductscience.org/library/papers/32466131 | PubMed |
| 20 | 33723374 | Beyond DNA repair and chromosome instability-Fanconi anaemia as a cellular senescence-associated syndrome. | Cell Death Differ | 2021 | https://conductscience.org/library/papers/33723374 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41814545 | Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure. | Stem Cells Transl Med | 2026 | https://conductscience.org/library/papers/41814545 | PubMed |
| 41303409 | Novel Therapeutic Strategy for Renal Cell Carcinoma: Niclosamide Enhances Sunitinib Efficacy via DNA Repair and Cell Cycle Pathways. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303409 | PubMed |
| 41155398 | Beyond Hematologic Malignancies: Colorectal Cancer as a Solid Tumor Manifestation of Inherited Bone Marrow Failure Syndromes. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41155398 | PubMed |
| 40594369 | Feasibility of long-read sequencing to identify molecular alterations in an Indonesian cohort of locally advanced to advanced nasopharyngeal cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40594369 | PubMed |
| 39519198 | Translational Research on Azacitidine Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2). | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39519198 | PubMed |
| 39375712 | FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy. | J Transl Med | 2024 | https://conductscience.org/library/papers/39375712 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37573408
GET https://conductscience.org/api/papers/v1/37573408/references?page=2